## Protocol Section
### Identification Module
**NCT ID:** NCT03635879

**Brief Title:** Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides

**Official Title:** A Phase 1, Single-Center, Pilot, Single-Dose, 6-Way Crossover Study to Compare Six Formulations of Medium Chain Triglycerides on the Pharmacokinetics of Ketone Body Production

#### Organization Study ID Info
**ID:** AX-18-018_PK
#### Organization
**Class:** INDUSTRY
**Full Name:** Cerecin
### Status Module
#### Completion Date
**Date:** 2019-04-16

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2018-09-27

**Type:** ACTUAL

**Last Update Submit Date:** 2018-09-25

**Overall Status:** WITHDRAWN

#### Primary Completion Date
**Date:** 2019-04-16

**Type:** ESTIMATED

#### Start Date
**Date:** 2019-02-13

**Type:** ESTIMATED

**Status Verified Date:** 2018-09

#### Study First Post Date
**Date:** 2018-08-17
**Type:** ACTUAL
**Study First Submit Date:** 2018-08-16
**Study First Submit QC Date:** 2018-08-16
**Why Stopped:** Study redesign
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** Cerecin

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Is US Export:** True

**Oversight Has DMC:** False

### Description Module

**Brief Summary:** This is a Phase I, open label, randomized, 6-way crossover, pilot PK study

**Detailed Description:** 12 healthy, male subjects enrolled, subject will be randomized to receive a single dose of one of six treatment, with a 2 day washout in between each dosing period.

### Conditions Module

**Conditions:**

- Alzheimer Disease

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** CROSSOVER

##### Masking Info

**Masking:** NONE

**Primary Purpose:** OTHER

#### Enrollment Info

**Type:** ACTUAL

**Phases:**

- PHASE1

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Vitaflo MCTprocal, single dose (20 g MCT)

**Intervention Names:**

- Other: MCTprocal medical food

**Label:** MCTprocal medical food

**Type:** ACTIVE_COMPARATOR

#### Arm Group 2

**Description:** Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)

**Intervention Names:**

- Other: Milk/tricaprilin oil blend

**Label:** Milk/tricaprilin oil blend

**Type:** ACTIVE_COMPARATOR

#### Arm Group 3

**Description:** AC-1207 liquid, single dose (20 g tricaprilin)

**Intervention Names:**

- Other: AC-1207

**Label:** AC-1207

**Type:** ACTIVE_COMPARATOR

#### Arm Group 4

**Description:** AC-1205 liquid, single dose (20 g tricaprilin)

**Intervention Names:**

- Other: AC-1205

**Label:** AC-1205

**Type:** ACTIVE_COMPARATOR

#### Arm Group 5

**Description:** AC-1206 liquid, single dose (20 g tricaprilin)

**Intervention Names:**

- Other: AC-1206

**Label:** AC-1206

**Type:** ACTIVE_COMPARATOR

#### Arm Group 6

**Description:** AC-1206 liquid, single dose (20 g tricaprilin)

**Intervention Names:**

- Drug: AC-1202

**Label:** AC-1202

**Type:** EXPERIMENTAL

### Interventions

#### Intervention 1

**Arm Group Labels:**

- MCTprocal medical food

**Description:** 32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1

**Name:** MCTprocal medical food

**Type:** OTHER

#### Intervention 2

**Arm Group Labels:**

- Milk/tricaprilin oil blend

**Description:** 154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1

**Name:** Milk/tricaprilin oil blend

**Type:** OTHER

#### Intervention 3

**Arm Group Labels:**

- AC-1207

**Description:** AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1

**Name:** AC-1207

**Type:** OTHER

#### Intervention 4

**Arm Group Labels:**

- AC-1205

**Description:** AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1

**Name:** AC-1205

**Type:** OTHER

#### Intervention 5

**Arm Group Labels:**

- AC-1206

**Description:** AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1

**Name:** AC-1206

**Type:** OTHER

#### Intervention 6

**Arm Group Labels:**

- AC-1202

**Description:** AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1

**Name:** AC-1202

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** Area Under the Curve (AUC) AUC 0 - last

**Measure:** Total ketones

**Time Frame:** 1 day

**Description:** AUC 0 - 4

**Measure:** Total ketones

**Time Frame:** 1 day

**Description:** AUC 0 - 6

**Measure:** Total ketones

**Time Frame:** 1 day

**Description:** AUC 0 - 8

**Measure:** Total ketones

**Time Frame:** 1 day

**Description:** Maximum Plasma Concentration (Cmax)

**Measure:** Total ketones

**Time Frame:** 1 day

**Description:** AUC 0 - last

**Measure:** B-hydroxybutyrate

**Time Frame:** 1 day

**Description:** AUC 0 - 4

**Measure:** B-hydroxybutyrate

**Time Frame:** 1 day

**Description:** AUC 0 - 6

**Measure:** B-hydroxybutyrate

**Time Frame:** 1 day

**Description:** AUC 0 - 8

**Measure:** B-hydroxybutyrate

**Time Frame:** 1 day

**Description:** Cmax

**Measure:** B-hydroxybutyrate

**Time Frame:** 1 day

**Description:** AUC 0 - last

**Measure:** Acetoacetate

**Time Frame:** 1 day

**Description:** AUC 0 - 4

**Measure:** Acetoacetate

**Time Frame:** 1 day

**Description:** AUC 0 - 6

**Measure:** Acetoacetate

**Time Frame:** 1 day

**Description:** AUC 0 - 8

**Measure:** Acetoacetate

**Time Frame:** 1 day

**Description:** Cmax

**Measure:** Acetoacetate

**Time Frame:** 1 day

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

1. Healthy, adult, male 18 55 years of age, inclusive, at Screening.
2. Continuous non smoker who has not used nicotine containing products for at least 3 months prior to Day -1 of Period 1 and throughout the study based on self-reporting.
3. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening.
4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. At screening, subjects must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ the upper limit of normal and triglyceride levels must be \< 250 mg/dL.
5. Hemoglobin levels ≥ the lower limit of normal at Screening and Day -1 of Period 1.
6. A non vasectomized subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to Day -1 of Period 1. A subject who has been vasectomized less than 4 months prior to Day -1 of Period 1 must follow the same restrictions as a non vasectomized male).
7. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria:

1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
4. History or presence of alcoholism or drug abuse within the past year prior to Day -1 of Period 1.
5. History or presence of galactosemia or hypersensitivity or idiosyncratic reaction to the study drugs, related compounds, milk, palm or coconut oil, or soy.
6. History or presence of symptomatic diverticular disease, uncontrolled gastroesophageal reflux disease, ulcers, inflammatory bowel disease, irritable bowel syndrome or recurrent diarrhea, or gout.
7. Positive urine drug results at Screening or Check-in.
8. Positive alcohol results at Screening or Check-in. One repeat assessment is permitted.
9. Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at Screening. One repeat assessment is permitted.
11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at Screening.
12. QTcF interval is \>460 msec or subject has ECG findings deemed abnormal with clinical significance by the PI or designee at Screening.
13. Estimated creatinine clearance ≤ 80 mL/min at Screening.
14. Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to Day -1 of Period 1 and throughout the study. Acetaminophen (up to 2 g per 24 hours) may be permitted during the study.
15. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 28 days prior to Day -1 of Period 1 and throughout the study.
16. Has been following a ketogenic diet, in the opinion of the PI or designee, within 2 weeks prior to Day -1 of Period 1.
17. Is lactose intolerant.
18. Is unable to complete the standard breakfast prior to dosing on Day 1 of each Period.
19. Donation of blood or significant blood loss within 56 days prior to Day -1 of Period 1.
20. Plasma donation within 7 days prior to Day -1 of Period 1.
21. Participation in another clinical study within 28 days prior to Day -1 of Period 1. The 28-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day -1 of Period 1 of the current study.

**Healthy Volunteers:** True

**Maximum Age:** 55 Years

**Minimum Age:** 18 Years

**Sex:** MALE

**Standard Ages:**

- ADULT

### IPD Sharing Statement Module

**IPD Sharing:** NO

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000003704

- Term: Dementia

- ID: D000001927

- Term: Brain Diseases

- ID: D000002493

- Term: Central Nervous System Diseases

- ID: D000009422

- Term: Nervous System Diseases

- ID: D000024801

- Term: Tauopathies

- ID: D000019636

- Term: Neurodegenerative Diseases

- ID: D000019965

- Term: Neurocognitive Disorders

- ID: D000001523

- Term: Mental Disorders

### Condition Browse Module - Browse Branches

- Abbrev: BC10

- Name: Nervous System Diseases

- Abbrev: BXM

- Name: Behaviors and Mental Disorders

- Abbrev: All

- Name: All Conditions

- Abbrev: Rare

- Name: Rare Diseases

### Condition Browse Module - Browse Leaves

- ID: M3885

- Name: Alzheimer Disease

- Relevance: HIGH

- As Found: Alzheimer's Disease

- ID: M6904

- Name: Dementia

- Relevance: LOW

- As Found: Unknown

- ID: M5204

- Name: Brain Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M5742

- Name: Central Nervous System Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M23002

- Name: Tauopathies

- Relevance: LOW

- As Found: Unknown

- ID: M21558

- Name: Neurodegenerative Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M21836

- Name: Neurocognitive Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M4815

- Name: Mental Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M14473

- Name: Psychotic Disorders

- Relevance: LOW

- As Found: Unknown

- ID: T2192

- Name: Familial Alzheimer Disease

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000000544

- Term: Alzheimer Disease

### Misc Info Module

- Version Holder: 2024-05-24
